AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37875856 — intervention group
Group type: COMPARATOR
Intervention: Physical exercise
Number of subjects: 31
Study 37875869 — intervention group
Group type: EXPERIMENTAL
Intervention: PIPAC with cisplatin (10.5 mg/m2 in 150 mL NaCl 0.9%) and doxorubicin (2.1 mg/m2 in 50 mL NaCl 0.9%) followed by 2 cycles of FOLFOX every 6-7 weeks (total of 3 PIPACs and 6 cycles of FOLFOX).
Number of subjects: 0
Study 37875943 — intervention group
Group type: EXPERIMENTAL
Intervention: VHW-led, CDSS-assisted T2D care model including lifestyle counselling, first-line oral antidiabetic, lipid-lowering, and antiplatelet treatment guided by a tablet-based CDSS.
Number of subjects: 226
Study 37875943 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving standard care by referral to a health facility for T2D management.
Number of subjects: 226
Study 37875943 — intervention group
Group type: EXPERIMENTAL
Intervention: VHW-led, CDSS-assisted T2D care model.
Number of subjects: 226
Study 37875962 — intervention group
Group type: EXPERIMENTAL
Intervention: Hans Kai program (intervention group, n=70)
Number of subjects: 105
Study 37875962 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group, n=35)
Number of subjects: 105
Study 37875971 — intervention group
Group type: EXPERIMENTAL
Intervention: PT + MR (Mobility Rehab)
Number of subjects: 28
Study 37875971 — intervention group
Group type: COMPARATOR
Intervention: PT alone
Number of subjects: 28
Study 37875997 — intervention group
Group type: EXPERIMENTAL
Intervention: Microinvasive pars plana vitrectomy (PPV) combined with internal limiting membrane (ILM) peeling
Number of subjects: 102
Study 37875997 — intervention group
Group type: COMPARATOR
Intervention: Conbercept intravitreal injection (IVC)
Number of subjects: 102
Study 37876018 — intervention group
Group type: EXPERIMENTAL
Intervention: HoNOS-13 questionnaire (13-item version including medication compliance)
Number of subjects: 609
Study 37876018 — intervention group
Group type: COMPARATOR
Intervention: HoNOS-12 questionnaire (12-item version)
Number of subjects: 609
Study 37876046 — intervention group
Group type: EXPERIMENTAL
Intervention: Damoctocog alfa pegol (prophylaxis every 3-4 days, median infusion dose of 37.5 IU/kg)
Number of subjects: 268
Study 37876056 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomography-guided nasotracheal intubation procedure
Number of subjects: 60
Study 37876056 — intervention group
Group type: COMPARATOR
Intervention: Control group (group A - easy intubation)
Number of subjects: 60
Study 37876056 — intervention group
Group type: COMPARATOR
Intervention: Control group (group B - difficult intubation)
Number of subjects: 60
Study 37876229 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors (canagliflozin and dapagliflozin)
Number of subjects: 8483
Study 37876374 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative oxygenation strategy (target arterial saturations 92-96%)
Number of subjects: 300
Study 37876374 — intervention group
Group type: COMPARATOR
Intervention: Liberal oxygenation strategy (target 97-100%)
Number of subjects: 300
Study 37876540 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide monotherapy
Number of subjects: 68
Study 37876540 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide plus cabergoline
Number of subjects: 68
Study 37876540 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide monotherapy and combination therapy
Number of subjects: 68
Study 37876540 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 68
Study 37876731 — intervention group
Group type: EXPERIMENTAL
Intervention: HSK21542
Number of subjects: 0
Study 37876886 — intervention group
Group type: EXPERIMENTAL
Intervention: Acacia 5 g daily
Number of subjects: 51
Study 37876886 — intervention group
Group type: EXPERIMENTAL
Intervention: Acacia 10 g daily
Number of subjects: 51
Study 37876886 — intervention group
Group type: COMPARATOR
Intervention: Microcrystalline cellulose (MCC) 10 g daily
Number of subjects: 51
Study 37876886 — intervention group
Group type: EXPERIMENTAL
Intervention: All dietary treatment arms (Acacia 5 g/d, Acacia 10 g/d, MCC)
Number of subjects: 51
Study 37876886 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 51
Study 37876998 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-low-dose CT (ULDCT)
Number of subjects: 294
Study 37876998 — intervention group
Group type: COMPARATOR
Intervention: Chest X-ray (CXR)
Number of subjects: 294
Study 37877219 — intervention group
Group type: EXPERIMENTAL
Intervention: Third dose of ZF2001 after 3-4 months
Number of subjects: 480
Study 37877219 — intervention group
Group type: EXPERIMENTAL
Intervention: Third dose of ZF2001 after 5-6 months
Number of subjects: 480
Study 37877219 — intervention group
Group type: EXPERIMENTAL
Intervention: Third dose of ZF2001 after 7-9 months
Number of subjects: 480
Study 37877219 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterologous BBIBP-CorV/ZF2001 prime-boost vaccination
Number of subjects: 480
Study 37877219 — intervention group
Group type: EXPERIMENTAL
Intervention: Older participants
Number of subjects: 480
Study 37877260 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 150 mg/kg
Number of subjects: 50
Study 37877260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 37877369 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib treatment
Number of subjects: 28
Study 37877369 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study 37877375 — intervention group
Group type: EXPERIMENTAL
Intervention: Pocock test
Number of subjects: 0
Study 37877375 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian Beta-Binomial models with weak priors
Number of subjects: 0
Study 37877375 — intervention group
Group type: EXPERIMENTAL
Intervention: O'Brien-Fleming test
Number of subjects: 0
Study 37877375 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-Binomial models with strong priors
Number of subjects: 0
Study 37877375 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified SPRT method
Number of subjects: 0
Study 37877609 — intervention group
Group type: EXPERIMENTAL
Intervention: Sigh breaths plus usual care (sigh volumes producing plateau pressures of 35 cm H2O or 40 cm H2O for patients with BMI >35, delivered once every 6 minutes)
Number of subjects: 524
Study 37877609 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 524
Study 37877609 — intervention group
Group type: EXPERIMENTAL
Intervention: Sigh breaths plus usual care
Number of subjects: 524
Study 37877585 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C administered intravenously every 6 hours for 96 hours (maximum of 16 doses)
Number of subjects: 2580
Study 37877585 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo or no vitamin C)
Number of subjects: 2580
Study 37877800 — intervention group
Group type: EXPERIMENTAL
Intervention: B-cell receptor repertoire analysis using IGHV spectratyping and next-generation sequencing of peripheral blood B-cell genomic DNA
Number of subjects: 14
Study 37877800 — intervention group
Group type: EXPERIMENTAL
Intervention: B-cell receptor repertoire analysis
Number of subjects: 14
Study 37877913 — intervention group
Group type: EXPERIMENTAL
Intervention: M-TEER with the fourth-generation M-TEER device
Number of subjects: 1164
Study 37878148 — intervention group
Group type: COMPARATOR
Intervention: Normal weight
Number of subjects: 1456
Study 37878148 — intervention group
Group type: EXPERIMENTAL
Intervention: Underweight
Number of subjects: 1456
Study 37878201 — intervention group
Group type: EXPERIMENTAL
Intervention: Religious fasting (intermittent fasting)
Number of subjects: 0
Study 37878201 — intervention group
Group type: EXPERIMENTAL
Intervention: Five questionnaires
Number of subjects: 0
Study 37878217 — intervention group
Group type: EXPERIMENTAL
Intervention: Promotora-based intervention (education, appointment reminders, assistance navigating the healthcare system)
Number of subjects: 94
Study 37878217 — intervention group
Group type: EXPERIMENTAL
Intervention: Promotora-based intervention
Number of subjects: 94
Study 37878217 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care alone
Number of subjects: 94
Study 37878295 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) in addition to optimal medical therapy
Number of subjects: 610
Study 37878295 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy alone
Number of subjects: 610
Study 37878295 — intervention group
Group type: EXPERIMENTAL
Intervention: Extent of viable myocardium
Number of subjects: 610
Study 37878295 — intervention group
Group type: EXPERIMENTAL
Intervention: Extent of nonviable myocardium
Number of subjects: 610
Study 37878299 — intervention group
Group type: EXPERIMENTAL
Intervention: PVB-VATS
Number of subjects: 196
Study 37878299 — intervention group
Group type: COMPARATOR
Intervention: PVB-US
Number of subjects: 196
Study 37878305 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic pancreaticoduodenectomy
Number of subjects: 200
Study 37878362 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based safety and health program
Number of subjects: 131
Study 37878376 — intervention group
Group type: EXPERIMENTAL
Intervention: COMA-F intervention (mindfulness-based resiliency program)
Number of subjects: 15
Study 37878376 — intervention group
Group type: EXPERIMENTAL
Intervention: COMA-F intervention
Number of subjects: 15
Study 37878483 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (2000 IU/day)
Number of subjects: 25671
Study 37878483 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation (1 g/day)
Number of subjects: 25671
Study 37878483 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25671
Study 37878497 — intervention group
Group type: EXPERIMENTAL
Intervention: WARS1 levels in sepsis patients without monocytopenia
Number of subjects: 74
Study 37878497 — intervention group
Group type: EXPERIMENTAL
Intervention: WARS1 levels in sepsis patients (all patients)
Number of subjects: 74
Study 37878497 — intervention group
Group type: EXPERIMENTAL
Intervention: AUROC of WARS1 at admission for mortality in patients without monocytopenia
Number of subjects: 74
Study 37878497 — intervention group
Group type: EXPERIMENTAL
Intervention: AUROC of WARS1 at 24 h for mortality in patients without monocytopenia
Number of subjects: 74
Study 37878497 — intervention group
Group type: EXPERIMENTAL
Intervention: AUROC of CRP at admission for mortality in patients without monocytopenia
Number of subjects: 74
Study 37878497 — intervention group
Group type: EXPERIMENTAL
Intervention: AUROC of CRP at 24 h for mortality in patients without monocytopenia
Number of subjects: 74
Study 37878497 — intervention group
Group type: EXPERIMENTAL
Intervention: AUROC of procalcitonin at admission for mortality in patients without monocytopenia
Number of subjects: 74
Study 37878497 — intervention group
Group type: EXPERIMENTAL
Intervention: AUROC of procalcitonin at 24 h for mortality in patients without monocytopenia
Number of subjects: 74
Study 37878497 — intervention group
Group type: EXPERIMENTAL
Intervention: AUROC of WARS1 at admission for mortality in patients with monocytopenia
Number of subjects: 74
Study 37878497 — intervention group
Group type: EXPERIMENTAL
Intervention: AUROC of WARS1 at 24 h for mortality in patients with monocytopenia
Number of subjects: 74
Study 37878624 — intervention group
Group type: EXPERIMENTAL
Intervention: GPC-100 + Propranolol
Number of subjects: 0
Study 37878624 — intervention group
Group type: EXPERIMENTAL
Intervention: GPC-100
Number of subjects: 0
Study 37878624 — intervention group
Group type: COMPARATOR
Intervention: G-CSF
Number of subjects: 0
Study 37878624 — intervention group
Group type: COMPARATOR
Intervention: G-CSF + Plerixafor
Number of subjects: 0
Study 37878675 — intervention group
Group type: EXPERIMENTAL
Intervention: PRGN-2012 treatment at the highest dose
Number of subjects: 0
Study 37878675 — intervention group
Group type: EXPERIMENTAL
Intervention: PRGN-2012 treatment
Number of subjects: 0
Study 37878786 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy (90 mg twice daily) after <1 month of DAPT (n=1426)
Number of subjects: 2850
Study 37878786 — intervention group
Group type: COMPARATOR
Intervention: Ticagrelor-based DAPT for 12 months (n=1424)
Number of subjects: 2850
Study 37879047 — intervention group
Group type: EXPERIMENTAL
Intervention: Axicabtagene ciloleucel (axi-cel) infusion (2 × 10^6 CAR T cells per kg) after leukapheresis and lymphodepleting chemotherapy
Number of subjects: 104
Study 37879047 — intervention group
Group type: EXPERIMENTAL
Intervention: Axicabtagene ciloleucel (axi-cel) infusion
Number of subjects: 104
Study 37879077 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin administered at 0.6 mg/m2 on day 1 and 0.3 mg/m2 on day 8 of cycle 1, then at 0.3 mg/m2 on days 1 and 8 of cycles 2-6.
Number of subjects: 26
Study 37879077 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin
Number of subjects: 26
Study 37879193 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed IV catheter system (BD Nexiva™)
Number of subjects: 38
Study 37879193 — intervention group
Group type: COMPARATOR
Intervention: Peripheral open IV catheter (BD Insyte™ Autoguard™)
Number of subjects: 38
Study 37879242 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual-reality exposure treatment (VRET)
Number of subjects: 186
Study 37879393 — intervention group
Group type: EXPERIMENTAL
Intervention: Returning genetic results on arsenic metabolism efficiency to inefficient metabolizers (high-risk)
Number of subjects: 309
Study 37879393 — intervention group
Group type: EXPERIMENTAL
Intervention: Returning genetic results on arsenic metabolism efficiency to efficient metabolizers (low-risk)
Number of subjects: 309
Study 37879393 — intervention group
Group type: COMPARATOR
Intervention: One-on-one educational intervention (baseline information on arsenic effects and exposure reduction)
Number of subjects: 309
Study 37879490 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT-guided PCI
Number of subjects: 2008
Study 37879490 — intervention group
Group type: COMPARATOR
Intervention: IVUS-guided PCI
Number of subjects: 2008
Study 37879536 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivonescimab 10 mg/kg Q3W
Number of subjects: 108
Study 37879536 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivonescimab 20 mg/kg Q2W
Number of subjects: 108
Study 37879536 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivonescimab 20 mg/kg Q3W
Number of subjects: 108
Study 37879536 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivonescimab 30 mg/kg Q3W
Number of subjects: 108
Study 37879536 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivonescimab (all doses)
Number of subjects: 108
Study 37879695 — intervention group
Group type: EXPERIMENTAL
Intervention: ASTX727 (demethylating agent)
Number of subjects: 27
Study 37879695 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 27
Study 37879700 — intervention group
Group type: EXPERIMENTAL
Intervention: CURATE.AI COR-Tx platform intervention, 10-week personalized digital intervention, three times a week
Number of subjects: 15
Study 37879701 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation intervention for family carers (administered in 2-hour sessions over 9 weeks)
Number of subjects: 111
Study 37879701 — intervention group
Group type: EXPERIMENTAL
Intervention: Service utilisation measured during a 12-month period preintervention, a 12-month period postintervention, and during a 12-24-month period post-intervention
Number of subjects: 111
Study 37879858 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 121
Study 37879858 — intervention group
Group type: COMPARATOR
Intervention: Exercise with optional delayed surgery
Number of subjects: 121
Study 37879880 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary flow reserve (CFR) and index of microvascular resistance (IMR) measured in the culprit vessel after primary percutaneous coronary intervention.
Number of subjects: 102
Study 37879886 — intervention group
Group type: EXPERIMENTAL
Intervention: NUC-treated patients
Number of subjects: 152
Study 37879886 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated HBeAg(+) patients
Number of subjects: 152
Study 37879886 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated HBeAg(-) patients
Number of subjects: 152
Study 37879886 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated chronic infection patients
Number of subjects: 152
Study 37879886 — intervention group
Group type: COMPARATOR
Intervention: Undetectability of cirB-RNA
Number of subjects: 152
Study 37879886 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined undetectability of cirB-RNA and HBcrAg in untreated HBeAg(-) patients
Number of subjects: 152
Study 37880023 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic enzyme replacement therapy (PERT)
Number of subjects: 26025
Study 37880076 — intervention group
Group type: EXPERIMENTAL
Intervention: No adjuvant therapy for patients with longitudinal undetectable MRD
Number of subjects: 180
Study 37880168 — intervention group
Group type: EXPERIMENTAL
Intervention: LMWH prophylaxis guided by peak aFXa levels (group A)
Number of subjects: 858
Study 37880168 — intervention group
Group type: EXPERIMENTAL
Intervention: LMWH prophylaxis guided by trough aFXa levels (group B)
Number of subjects: 858
Study 37880168 — intervention group
Group type: COMPARATOR
Intervention: Fixed dose of LMWH (group C)
Number of subjects: 858
Study 37880167 — intervention group
Group type: EXPERIMENTAL
Intervention: PROMED-EX (diet+exercise)
Number of subjects: 105
Study 37880167 — intervention group
Group type: EXPERIMENTAL
Intervention: PROMED (diet only)
Number of subjects: 105
Study 37880167 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 105
Study 37880303 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 weeks of exercise training
Number of subjects: 169
Study 37880303 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 169
Study 37880316 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 720
Study 37880389 — intervention group
Group type: EXPERIMENTAL
Intervention: ABBV-467
Number of subjects: 8
Study 37880447 — intervention group
Group type: EXPERIMENTAL
Intervention: Lichtenstein technique
Number of subjects: 48
Study 37880447 — intervention group
Group type: COMPARATOR
Intervention: TAPP technique
Number of subjects: 48
Study 37880447 — intervention group
Group type: EXPERIMENTAL
Intervention: Lichtenstein and TAPP techniques
Number of subjects: 48
Study 37880499 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency-device based renal denervation (RDN)
Number of subjects: 58
Study 37880568 — intervention group
Group type: EXPERIMENTAL
Intervention: Threat periods
Number of subjects: 51
Study 37880568 — intervention group
Group type: EXPERIMENTAL
Intervention: Threat-induced anxiety
Number of subjects: 51
Study 37880581 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose oral thiamine treatment for chronic fatigue
Number of subjects: 0
Study 37880591 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Frailty Scale (CFS) assessment
Number of subjects: 4235
Study 37880591 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey on staff experience of using CFS
Number of subjects: 4235
Study 37880639 — intervention group
Group type: EXPERIMENTAL
Intervention: Connect through PLAY afterschool program intervention
Number of subjects: 113
Study 37880682 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolism-related prognostic model; validated using multiple external datasets.
Number of subjects: 0
Study 37880682 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk group identified through consensus clustering algorithm.
Number of subjects: 0
Study 37880682 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolism-related prognostic model.
Number of subjects: 0
Study 37880682 — intervention group
Group type: EXPERIMENTAL
Intervention: Model genes expression levels in IMvigor210, GSE111636, GSE176307, Truce01 cohorts.
Number of subjects: 0
Study 37880682 — intervention group
Group type: EXPERIMENTAL
Intervention: Expression of model genes verified in BCa tissues and para-carcinoma tissues.
Number of subjects: 0
Study 37880704 — intervention group
Group type: COMPARATOR
Intervention: Good appetite
Number of subjects: 530
Study 37880704 — intervention group
Group type: COMPARATOR
Intervention: No fatigue
Number of subjects: 530
Study 37880704 — intervention group
Group type: COMPARATOR
Intervention: High albumin levels (> 36 g/L)
Number of subjects: 530
Study 37880704 — intervention group
Group type: COMPARATOR
Intervention: Lowest tertile of CRP/albumin ratio
Number of subjects: 530
Study 37880782 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile application for VHSGs and web interface for HC staff (intervention arm)
Number of subjects: 200
Study 37880782 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control arm)
Number of subjects: 200
Study 37880931 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural conception
Number of subjects: 94
Study 37880931 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted reproductive technology (ART)
Number of subjects: 94
Study 37880931 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine therapy before pregnancy
Number of subjects: 94
Study 37880931 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive disorders of pregnancy
Number of subjects: 94
Study 37880931 — intervention group
Group type: EXPERIMENTAL
Intervention: Newborn outcomes
Number of subjects: 94
Study 37881233 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone (0.15 mg/kg for study 302; 8 or 12 mg based on weight for study 4000)
Number of subjects: 363
Study 37881233 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone
Number of subjects: 363
Study 37881233 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 363
Study 37881307 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular injection of anti-TNF (adalimumab 160mg) followed by a second injection of adalimumab 80mg 2-3 weeks later.
Number of subjects: 84
Study 37881307 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection (saline [0.9% sodium chloride]) followed by a second injection of equivalent volume of placebo 2-3 weeks later.
Number of subjects: 84
Study 37881306 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise ACT (ExACT) for 28 days
Number of subjects: 50
Study 37881306 — intervention group
Group type: COMPARATOR
Intervention: Usual care (chest physiotherapy)
Number of subjects: 50
Study 37881306 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise ACT (ExACT)
Number of subjects: 50
Study 37881628 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic and/or histologic remission
Number of subjects: 73